[Form 4] Rhythm Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 snapshot: On 06/24/2025, Rhythm Pharmaceuticals (ticker RYTM) filed a Form 4 reporting new equity awards to director Lynn A. Tetrault.

• Stock options: 7,037 options with a $63.66 exercise price, expiring 06/23/2035. Vest in full on the earlier of 06/24/2026 or the day before the 2026 annual meeting, subject to continued board service.
• Restricted stock units (RSUs): 4,712 units; each RSU converts into one common share. Vesting schedule matches the option grant; no expiration date.
• Post-grant holdings: 7,037 derivative securities (options) and 4,712 RSUs are now reported as beneficially owned. No common shares were bought or sold, and no dispositions occurred.

The filing reflects routine director compensation designed to align incentives; it does not disclose any share sales, purchases with cash, or changes to non-derivative ownership.

Insights

Corporate Governance Expert

TL;DR: Routine equity awards (7,037 options, 4,712 RSUs) to RYTM director; no buy/sell activity—neutral for investors.

The Form 4 grants Lynn A. Tetrault standard director compensation: time-based vesting options priced at $63.66 and matching RSUs. No monetary transactions occurred, so cash flow and immediate dilution are negligible. Vesting tied to continued board service encourages retention and shareholder alignment. Because the volumes are modest relative to typical biotech share counts and no market transactions were executed, the disclosure is primarily informational rather than market-moving.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TETRAULT LYNN A.

(Last) (First) (Middle)

C/O RHYTHM PHARMACEUTICALS, INC.

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$63.66	06/24/2025		A		7,037		(1)	06/23/2035	Common Stock	7,037	$0	7,037	D
Restricted Stock Units	(2)	06/24/2025		A		4,712		(3)	(3)	Common Stock	4,712	$0	4,712	D

Explanation of Responses:

1. The options fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date.

2. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

3. The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

	/s/ Stephen Vander Stoep, attorney-in-fact for Lynn A. Tetrault	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did RYTM director Lynn A. Tetrault receive on 06/24/2025?

She received 7,037 stock options at a $63.66 exercise price and 4,712 restricted stock units (RSUs).

When do the newly granted RYTM options and RSUs vest?

Both awards fully vest on the earlier of 06/24/2026 or the day before Rhythm Pharmaceuticals’ 2026 annual shareholder meeting.

Did Lynn A. Tetrault buy or sell any RYTM common shares in this Form 4?

No. The Form 4 reports only equity grants; no purchases or sales of common stock occurred.

What is the expiration date of the stock options granted to the RYTM director?

The options expire on 06/23/2035.

How many derivative securities does Lynn A. Tetrault beneficially own after the transaction?

She now reports 7,037 options and 4,712 RSUs as beneficially owned.